Our Vision:
- Integrate biomaterials design with drug and cell-based technologies
- Engineer/validate new combinational health care products
- Translate clinical needs into therapies
Disciplines:
In Vitro Disease Models (Organoids/Tissue on a Chip)
- Real-Time 4D Imaging
- 3D Printing Additive Manufacturing
Drug Delivery Systems/Sensing/Theranostics
- Advanced Characterization: Materials, Tissues, Cells, Scaffolds
- Big Data, Quantitative Analysis, & Modeling
Tissue Engineering and Regenerative Medicine
- Stem Cells nad Progenitor Cells
- Cell-Matrix Signaling, Mechano-Sensing
Through this materials-centric approach, we will provide next-generation, disruptive therapeutic interventions for a broad spectrum of diseases with unmet medical needs.
News coverage of activity within the IRT
Saleh talks about life in the Bryant Group, future career as teacher and researcher
Fifth-year chemical and biological PhD candidate Leila Saleh works at the crossroads of immunology and engineering in the Bryant Research Group. During her time at CU Boulder, she has worked with professors Stephanie Bryant, Kristi Anseth and Jenifer Cha in various capacities – giving her a great chance to see how all three balance research and teaching, and shaping her post-graduation plans. Read more
Machine learning technology may help doctors identify and treat infections faster in newborns
New research using machine learning technology may help doctors identify pathogens in blood samples in a fraction of the time of current methods, leading to faster deployments of life-saving treatments in patients suffering from sepsis, especially newborns. Read more
Garcea and Randolph awarded Gates Foundation grant for vaccine research
New research is showing encouraging results in stabilizing vaccines and circumventing the refrigeration requirement, earning an additional $1.2 million in grant funding from the Bill and Melinda Gates Foundation. Read more